300363.SZ
300363.SZ
CNE100001S57
PORTON
Loading chart...

Company Profile

Porton Pharma Solutions Ltd. provides contract development and manufacturing organization (CDMO) solutions for small molecules, tides, biologics, and conjugates from pre-clinical to commercial in China and internationally. It has a strategic collaboration with Aojin Life Sciences to advance XDC conjugate drugs; and strategic partnership with Dragon Sail Pharmaceutical to build a new ecosystem for ADC drug development, production, and supply chain. It also offers crystallization, bio catalysis, metal catalysis, flow chemistry, prep-chromatography, and milling. Porton Pharma Solutions Ltd. was formerly known as Porton Fine Chemicals Ltd. and changed its name to Porton Pharma Solutions Ltd. in January 2018. The company was incorporated in 2005 and is headquartered in Chongqing, China.

Related stocks

000766.SZ
000766.SZ • China
TONGHUA GOLDEN HORSE
14.97 CNY
2.16B USD 1Y -40.1%
603707.SS
603707.SS • China
NANJING KING-FRIEND BIOCHEMICAL
8.18 CNY
1.98B USD 1Y -21.6%
300725.SZ
300725.SZ • China
PHARMABLOCK
51.01 CNY
1.78B USD 1Y +22.3%
300601.SZ
300601.SZ • China
KANGTAI BIOLOGICAL
13.44 CNY
2.25B USD 1Y -20.6%
688321.SS
688321.SS • China
SHENZHEN CHIPSCREEN BIOSCIENCES
24.31 CNY
1.61B USD 1Y -23.6%
600216.SS
600216.SS • China
ZHEJIANG MEDICINE
12.59 CNY
1.81B USD 1Y -12.9%
1681.HK
1681.HK • China
CONSUN PHARMA
14.85 HKD
1.59B USD 1Y -13.6%
600518.SS
600518.SS • China
KANGMEI PHARMACEUTICAL CO LTD
1.35 CNY
2.79B USD 1Y -33.8%

Key Metrics & Overview

Detailed metrics & financial data of the company

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
56.9% p.a.
Max Drawdown (5Y)
-88.8%
Sharpe Ratio (5Y)
-0.45
Beta Factor
0.55
Size Class
Large Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
Unprofitable business model: The company is currently generating net losses.
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (56.9% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -89.2% in the extended horizon.
ende